Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 17/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.61 |
| ▸ | RORA | P35398 | 4/20 | 0.61 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.61 |
| ▸ | RORB | Q92753 | 4/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15628949 | 0.83 | RORC (0.66) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5023196 | 0.82 | RORC (0.70) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15628993 | 0.82 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15629002 | 0.82 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15628937 | 0.82 | RORC (0.60) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL5021852 | 0.81 | RORC (0.66) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL18359167 | 0.81 | RORC (0.62) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15629063 | 0.81 | RORC (0.62) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL16823760 | 0.81 | RORC (0.80) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL18359194 | 0.80 | RORC (0.60) | RORCNR1I2RORANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |